Tissue factor pathway inhibitorAlternative Names: TFPI
Latest Information Update: 26 Jun 2002
At a glance
- Originator Nonindustrial source
- Class Anticoagulants; Lipoproteins
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atherosclerosis; Blood coagulation disorders; Reperfusion injury